Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer ...

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...

16:52 EST Biodexa Pharmaceuticals (BDRX ... and streamline your search for investment opportunities using Tipranks' Stock Screener Published first on TheFly – the ultimate source for real ...

September 26, 2024 Biodexa Pharmaceuticals PLC (Biodexa or the Company) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...